NCT00487916View on ClinicalTrials.gov

Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum

PHASE1CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

June 13, 2007

Primary Completion Date

February 5, 2009

Study Completion Date

February 5, 2009

Conditions

Malaria

Interventions

DRUG

AMA1-C1/ISA 720

Trial Locations (1)

Unknown

QIMR - CLive Berghofer Cancer Research Centre, Herston

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00487916 - Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum | Biotech Hunter | Biotech Hunter